3 results
6-K
EX-99.2
IFRX
InflaRx N.V.
1 Nov 23
Current report (foreign)
8:04am
patients in the study and we will close clinical sites in which no patients are being treated. Our decision to wind down this clinical study does … for emergency use as granted by the FDA, complete developing vilobelimab in other indications, including PG in our Phase III trial, and wind down the Phase II
6-K
EX-99.3
IFRX
InflaRx N.V.
1 Nov 23
Current report (foreign)
8:04am
in which no patients are currently being treated will be closed down. The decision to wind down this clinical study does not preclude InflaRx from
- Prev
- 1
- Next